CORT

Bristol Myers Squibb BMY announced mixed phase III results for admilparant, its investigational treatment for idiopathic pulmonary fibrosis (IPF). The company also reported positive results from the phase III ACTION-1 trial evaluating RYZ101 in advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). While RYZ101 met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS), admilparant met its primary endpoint only at the lower of the two doses tested. Consequently, the stock declined following the announcements despite the positive cancer trial results, reflecting investor concerns about admilparant's inconsistent dose response. While BMY stock opened higher, it reversed course and ended trading down 2.6% on Oct. 12. Shares of Bristol Myers have gained 6.8% year to date compared with the industry's growth of 2.6%. Image Source: Zacks Investment Research Admilparant is an investigational oral lysophosphatidic acid receptor 1 (LPA1) antagonist, which is being evaluated in adults with IPF. The phase III ALOFT-IPF trial evaluated admilparant at 60-mg and 120-mg doses, administered twice daily for at least 52 weeks, against placebo. Top-line results from the study showed that it met its primary endpoint at the 60-mg dose, with admilparant demonstrating a statistically significant improvement versus placebo in the absolute change in forced vital capacity (FVC) from baseline at week 52. FVC is an important measure of lung function, and slowing its decline is a key treatment objective in patients with IPF. The 120-mg dose slowed the decline in FVC but failed to achieve statistical significance. The mixed results across the two doses have likely disappointed investors, particularly given the positive efficacy signals reported in earlier-stage studies. In a global phase II trial, treatment with admilparant 60 mg twice daily for 26 weeks reduced the rate of lung function decline by 62% versus placebo in patients with IPF and a 69% reduction in patients with progressive pulmonary fibrosis (PPF). Although the phase III results support the drug's potential, the failure of the higher dose to meet statistical significance introduces some uncertainty regarding the consistency of its efficacy. The safety findings were encouraging. Admilparant demonstrated a well-tolerated safety profile at both doses, with low rates of discontinuation due to adverse events that were similar to placebo. IPF is characterized by irreversible scarring of lung tissue and a progressive decline in lung function. BMY will conduct a comprehensive evaluation of the ALOFT-IPF data and engage with health authorities to support planned regulatory submissions. The company expects top-line results from the fully enrolled phase III ALOFT-PPF trial in early 2027. The outcome will be key to determining whether admilparant can demonstrate broader efficacy across pulmonary fibrosis populations. In a separate announcement, BMY reported positive top-line results from the planned interim analysis of the phase III ACTION-1 study evaluating RYZ101 in patients with somatostatin receptor-positive GEP-NETs whose disease had progressed following treatment with Lu177-based therapy. The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in PFS, as assessed by blinded independent central review, compared with investigator's choice of standard of care. The comparator treatments included high-dose or high-frequency long-acting somatostatin analogues, everolimus or sunitinib. Safety results were consistent with the known safety profile of RYZ101. RYZ101 is an investigational targeted radiopharmaceutical therapy comprising DOTATATE linked to actinium-225, a potent alpha-emitting radioisotope. The positive ACTION-1 results mark a milestone for BMY's radiopharmaceutical portfolio. The study represents the first phase III trial to report results for an alpha-isotope-based targeted radiopharmaceutical therapy in any indication. The findings could support RYZ101's development as a potential treatment for patients with advanced GEP-NETs who have progressed following a Lu177-based therapy. The FDA granted RYZ101 Orphan Drug Designation for GEP-NETs in August 2026. Patients enrolled in the trial will continue to be followed for overall survival. BMY is undergoing a meaningful shift in its revenue mix, with its growth portfolio taking on a larger role and increasingly offsetting the pressure from mature products facing generic competition. Bristol Myers Squibb Company price-consensus-eps-surprise-chart | Bristol Myers Squibb Company Quote The company is actively reshaping its portfolio through new approvals, label expansions and pipeline development. The recent pipeline progress has been impressive as well. The FDA granted accelerated approval to iberdomide, in combination with daratumumab and hyaluronidase-fihj and dexamethasone under the brand name Zenbexus, for adults with multiple myeloma who have received at least one prior line of therapy. Zenbexus is the first FDA-approved cereblon E3 ligase modulator, adding a novel protein-degradation approach to BMY's oncology portfolio. The latest clinical updates provide a mixed picture of its pipeline progress. RYZ101's success in the phase III ACTION-1 study strengthens the company's radiopharmaceutical prospects. However, admilparant's mixed dose-level results in the phase III ALOFT-IPF trial introduce uncertainty, despite the statistically significant benefit demonstrated at the 60-mg dose and the favorable safety profile at both doses. Meanwhile, shares of Contineum Therapeutics CTNM plunged 36% following BMY's announcement. BMY's IPF study results create uncertainty for CTNM's investigational candidate PIPE-79 for IPF. Contineum is evaluating PIPE-791 in a phase II study. BMY currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the pharma/biotech sector are Amarin AMRN and Corcept Therapeutics CORT, currently sporting a Zacks Rank #1 (Strong Buy) each. You can see the complete list of today's Zacks #1 Rank stocks here. Over the past 60 days, loss per share estimates for Amarin have narrowed from 65 cents to 39 cents for 2026. Over the same period, estimates for 2027 loss per share have narrowed from 51 cents to 50 cents. Amarin's earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 62.27%. Over the past 60 days, earnings per share estimates for Corcept Therapeutics have increased from $1.13 to $1.86 for 2026. Over the same period, estimates for 2027 earnings per share have risen from $2.35 to $3.48. Corcept Therapeutics' earnings missed estimates in two of the trailing four quarters, beat in one and met in the other, with the average surprise being 240.74%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report Amarin Corporation PLC (AMRN) : Free Stock Analysis Report Corcept Therapeutics Incorporated (CORT) : Free Stock Analysis Report Contineum Therapeutics, Inc. (CTNM) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

UnitedHealth Group, Inc. UNH reported third-quarter 2026 adjusted earnings per share (EPS) of $4.69, which beat the Zacks Consensus Estimate of $4.12. The bottom line rose 60.6% year over year. Revenues declined 0.4% year over year to $112.7 billion. However, the top line beat the consensus mark by 1.2%. The quarterly results were aided by the strength witnessed in Optum Insight and Optum Rx. Medical cost management, pricing discipline and benefit design changes also contributed to the upside. However, weakness in Optum Health and declining memberships partially offset the positives. UnitedHealth Group Incorporated price-consensus-eps-surprise-chart | UnitedHealth Group Incorporated Quote UnitedHealth's third-quarter premium of $87.1 billion decreased from $89 billion a year ago but beat the consensus mark of $86 billion. UNH's adjusted medical care ratio (MCR) was 88.4% in the third quarter, which improved 150 bps from the year-ago period. MCR witnessed a decrease, backed by solid medical cost management, pricing discipline and benefit design changes. Medical costs of $77 billion declined from $80 billion a year ago. Third-quarter total operating costs of $106.1 billion decreased 2.5% year over year, benefiting from lower medical costs and operating costs. However, the figure was higher than our model estimate of $104.5 billion. The third-quarter 2026 operating cost ratio improved to 12.8% from 13.5% a year ago. UnitedHealth's adjusted operating earnings rose 45.2% year over year to $6.3 billion in the third quarter. Revenues of the health benefits business of UnitedHealth, UnitedHealthcare, declined 0.8% year over year to $86.3 billion in the third quarter. However, the metric beat the Zacks Consensus Estimate of $84.7 billion and our estimate of $82.8 billion. The UnitedHealthcare business catered to 48.3 million people as of Sept. 30, 2026, which fell 3.6% year over year. Adjusted earnings from operations amounted to $2.7 billion, up from $1.8 billion a year ago. The adjusted operating margin increased to 3.1% from 2.1% a year ago. Revenues in the Optum business line were $66.9 billion, which fell from $69.2 billion a year ago due to lower contribution from Optum Health. The figure missed the consensus mark of $67.1 billion. Optum's adjusted earnings from operations rose to $3.6 billion from $2.5 billion a year ago. The adjusted operating margin of 5.3% increased from 3.6%. UnitedHealth exited the third quarter with cash and short-term investments of $28.5 billion, which rose from the 2025-end level of $28.1 billion. Total assets of $312.8 billion increased from the $309.6 billion figure at 2025-end. Long-term debt, less current maturities, amounted to $68.7 billion, down from the $72.3 billion figure as of Dec. 31, 2025. Short-term borrowings and the current maturities of long-term debt were $5.6 billion. Total equity of $104.1 billion advanced from the 2025-end level of $100.1 billion. UnitedHealth generated operating cash flows of $25.1 billion in the first nine months of 2026, which grew from the prior-year figure of $18.6 billion. In the first nine months of 2026, it paid dividends worth $6.2 billion and repurchased $5 billion of stock. Management earlier anticipated revenues for 2026 above $439 billion, which are below the 2025 level due to planned right-sizing across operations. Adjusted EPS is now expected to be at least $20.5 for 2026, up from the previously guided range of $19.5-$20, indicating improving margins. Net margin was expected to be around 3.6%, up from 2.7% in 2025. The company earlier expected MCR to be 88.1% (± 25 bps) in 2026, down from 89.1% in 2025. The operating cost ratio was likely to be 12.8% (± 50 bps) in 2026. The tax rate was expected to be around 18.5%. Operating cash flows were estimated to be around $24 billion, up from the previous guidance of greater than $18 billion. UNH was expected to make repurchases of at least $5 billion and pay dividends worth $8 billion in 2026. Capital expenditure was estimated at $3.8 billion for the year. Furthermore, management earlier expected medical memberships to be within 46.945-47.495 million in 2026, with significant declines in commercial risk, Medicare Advantage and Medicaid heads. UNH currently carries a Zacks Rank #2 (Buy). Some other top-ranked stocks in the broader medical space are Phibro Animal Health Corporation PAHC, Corcept Therapeutics Incorporated CORT and TG Therapeutics, Inc. TGTX, each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here. The Zacks Consensus Estimate for Phibro Animal Health's current-quarter earnings is pegged at 77 cents per share, suggesting 5.5% year-over-year growth. PAHC beat earnings estimates in each of the trailing four quarters, with the average surprise being 18.4%. The consensus estimate for current-quarter revenues is pegged at $376.1 million, suggesting 3.4% year-over-year growth. The Zacks Consensus Estimate for Corcept Therapeutics' current-quarter earnings of 68 cents per share has remained stable over the past seven days. CORT beat earnings estimates in one of the trailing four quarters, met once and missed twice. The consensus estimate for current-quarter revenues is pegged at $329.2 million, suggesting 58.5% year-over-year growth. The Zacks Consensus Estimate for TG Therapeutics' current-quarter earnings of 37 cents per share has witnessed one upward revision in the past seven days, against no movement in the opposite direction. The consensus estimate for TGTX's current-quarter revenues is pegged at $247.2 million, suggesting 52.8% year-over-year growth. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report UnitedHealth Group Incorporated (UNH) : Free Stock Analysis Report Corcept Therapeutics Incorporated (CORT) : Free Stock Analysis Report TG Therapeutics, Inc. (TGTX) : Free Stock Analysis Report Phibro Animal Health Corporation (PAHC) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

It has been about a month since the last earnings report for United Therapeutics (UTHR). Shares have lost about 8% in that time frame, underperforming the S&P 500. But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is United Therapeutics due for a breakout? Well, first let's take a quick look at its most recent earnings report in order to get a better handle on the recent catalysts for United Therapeutics Corporation before we dive into how investors and analysts have reacted as of late. Q2 Earnings Beat Estimates, Revenues Miss Mark United Therapeutics reported second-quarter EPS of $7.27, beating the Zacks Consensus Estimate of $6.82. Earnings increased 13.4% year over year.Revenues in the quarter totaled $783.3 million, which missed the Zacks Consensus Estimate of $803 million. Revenues declined 2% year over year. Q2 Results in Detail Combined Tyvaso sales totaled $452.6 million, down 4% year over year due to lower revenues from nebulized Tyvaso. Tyvaso sales fell short of the Zacks Consensus Estimate of $469 million.Tyvaso DPI generated revenues of $326.6 million, climbing 4% year over year due to an increase in patient demand and some pricing benefits.Revenues from nebulized Tyvaso (treprostinil) were $126 million, down 18%, largely due to reduced U.S. demand despite modest price increases.Sales of Orenitram rose 1% year over year to $125.7 million.Remodulin (including Remunity Pump) sales declined 6% year over year to $126.3 million primarily due to lower demand in the United States despite an increase in international revenues.Unituxin sales were up 12% year over year to $65.2 million.Adcirca sales were $6.7 million, roughly consistent with the prior-year quarter.Research and development expenses were $146.3 million in the quarter, up 9% year over year, mainly due to higher spending on clinical programs and a rise in the fair value of contingent consideration liabilities related to acquired manufactured organ and organ alternative projects.Selling, general and administrative expenses declined 3% year over year to $206.7 million in the quarter.As of June 30, 2026, UTHR had cash, cash equivalents and investments of $3.8 billion compared with $3.5 billion as of March 31, 2026. In the past month, investors have witnessed a downward trend in estimates revision. The consensus estimate has shifted -7.92% due to these changes. Currently, United Therapeutics has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with a D. However, the stock was allocated a grade of B on the value side, putting it in the top 40% for value investors. Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in. Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Interestingly, United Therapeutics has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months. United Therapeutics is part of the Zacks Medical - Drugs industry. Over the past month, Corcept Therapeutics (CORT), a stock from the same industry, has gained 4.5%. The company reported its results for the quarter ended June 2026 more than a month ago. Corcept reported revenues of $256.15 million in the last reported quarter, representing a year-over-year change of +31.7%. EPS of $0.36 for the same period compares with $0.29 a year ago. For the current quarter, Corcept is expected to post earnings of $0.58 per share, indicating a change of +262.5% from the year-ago quarter. The Zacks Consensus Estimate has changed +4.9% over the last 30 days. Corcept has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of C. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report United Therapeutics Corporation (UTHR) : Free Stock Analysis Report Corcept Therapeutics Incorporated (CORT) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

A month has gone by since the last earnings report for Corcept Therapeutics (CORT). Shares have lost about 1.2% in that time frame, underperforming the S&P 500. But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Corcept due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Corcept reported second-quarter 2026 earnings of 36 cents per share, outperforming the Zacks Consensus Estimate of a loss of 4 cents. In the year-ago quarter, the company reported earnings of 29 cents. Second-quarter revenues rose nearly 32% year over year to $256.1 million and surpassed the Zacks Consensus Estimate of $216 million. Growth was driven by higher Korlym sales and contribution from the newly launched product, Lifyorli (relacorilant). Corcept’s top line consisted of product sales from Cushing’s syndrome drug Korlym and newly launched ovarian cancer drug Lifyorli. In the second quarter of 2026, product revenues from Korlym were $208.6 million, up 7.3% year over year. However, the metric missed our model estimate of $212.2 million. Lifyorli generated $47.6 million in the second quarter of 2026, reflecting its first quarter of commercial sales. Second-quarter operating expenses increased 28.1% year over year to $214.8 million. The rise reflected spending related to the Lifyorli launch and continued investment in the company’s Cushing’s syndrome business. Selling, general and administrative expenses surged 51.1% to $156.9 million. Research and development expenses declined 10.9% to $53.9 million. Corcept ended the June quarter with cash and investments of $544.6 million, up from $515.4 million as of March 31, 2026. Corcept raised its 2026 revenue guidance to $1.1-$1.2 billion from the previous $950 million to $1.05 billion. Management said that the revised outlook reflects strength across the endocrinology and oncology businesses. In the past month, investors have witnessed a upward trend in estimates revision. The consensus estimate has shifted 86.02% due to these changes. Currently, Corcept has a nice Growth Score of B, however its Momentum Score is doing a bit better with an A. However, the stock was allocated a score of D on the value side, putting it in the bottom 40% for value investors. Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in. Estimates have been trending upward for the stock, and the magnitude of these revisions looks promising. Interestingly, Corcept has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months. Corcept belongs to the Zacks Medical - Drugs industry. Another stock from the same industry, Summit Therapeutics PLC (SMMT), has gained 6.6% over the past month. More than a month has passed since the company reported results for the quarter ended June 2026. Summit Therapeutics reported revenues of $0 million in the last reported quarter, representing a year-over-year change of 0%. EPS of -$0.28 for the same period compares with -$0.76 a year ago. For the current quarter, Summit Therapeutics is expected to post a loss of $0.28 per share, indicating a change of +9.7% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days. Summit Therapeutics has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of F. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Corcept Therapeutics Incorporated (CORT) : Free Stock Analysis Report Summit Therapeutics PLC (SMMT) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Corcept (NASDAQ:CORT) and its peers. Looking ahead, the branded pharmaceutical industry is positioned for tailwinds from advancements in precision medicine, increasing adoption of AI to enhance drug development efficiency, and growing global demand for treatments addressing chronic and rare diseases. However, headwinds include heightened regulatory scrutiny, pricing pressures from governments and insurers, and the looming patent cliffs for key blockbuster drugs. Patent cliffs bring about competition from generics, forcing branded pharmaceutical companies back to the drawing board to find the next big thing. The 8 branded pharmaceuticals stocks we track reported a strong Q2. As a group, revenues beat analysts’ consensus estimates by 6.6%. Thankfully, share prices of the companies have been resilient as they are up 9.3% on average since the latest earnings results. Focusing on the powerful stress hormone that affects everything from metabolism to immune function, Corcept Therapeutics (NASDAQ:CORT) develops and markets medications that modulate cortisol to treat endocrine disorders, cancer, and neurological diseases. Corcept reported revenues of $256.1 million, up 31.7% year on year. This print exceeded analysts’ expectations by 21.6%. Overall, it was an incredible quarter for the company with a beat of analysts’ EPS estimates and full-year revenue guidance exceeding analysts’ expectations. Corcept achieved the biggest analyst estimate beat and highest full-year guidance raise of the whole group. Unsurprisingly, the stock is up 28.1% since reporting and currently trades at $119.05. Is now the time to buy Corcept? Access our full analysis of the earnings results here, it’s free. With roots dating back to 1887 and a transformative merger in 1989 that gave the company its current name, Bristol-Myers Squibb (NYSE:BMY) discovers, develops, and markets prescription medications for serious diseases including cancer, blood disorders, immunological conditions, and cardiovascular diseases. Bristol-Myers Squibb reported revenues of $12.97 billion, up 5.7% year on year, outperforming analysts’ expectations by 12.9%. The business had an incredible quarter with a beat of analysts’ EPS estimates and an impressive beat of analysts’ full-year EPS guidance estimates. The market seems happy with the results as the stock is up 7.3% since reporting. It currently trades at $67.72. Is now the time to buy Bristol-Myers Squibb? Access our full analysis of the earnings results here, it’s free. Originally spun off from Pfizer in 2013 as the world's largest pure-play animal health company, Zoetis (NYSE:ZTS) discovers, develops, and sells medicines, vaccines, diagnostic products, and services for pets and livestock animals worldwide. Zoetis reported revenues of $2.47 billion, flat year on year, falling short of analysts’ expectations by 1.5%. It was a disappointing quarter as it posted full-year revenue guidance missing analysts’ expectations and a significant miss of analysts’ full-year EPS guidance estimates. Zoetis delivered the weakest performance against analyst estimates, slowest revenue growth, and weakest full-year guidance update in the group. Interestingly, the stock is up 3.6% since the results and currently trades at $77.08. Read our full analysis of Zoetis’s results here. Founded in 1876 by a Civil War veteran and pharmacist frustrated with the poor quality of medicines, Eli Lilly (NYSE:LLY) discovers, develops, and manufactures pharmaceutical products for conditions including diabetes, obesity, cancer, immunological disorders, and neurological diseases. Eli Lilly reported revenues of $22.97 billion, up 47.7% year on year. This result surpassed analysts’ expectations by 11.4%. It was an exceptional quarter as it also put up a beat of analysts’ EPS estimates and an impressive beat of analysts’ full-year EPS guidance estimates. Eli Lilly pulled off the fastest revenue growth among its peers. The stock is up 14.6% since reporting and currently trades at $1,279. Read our full, actionable report on Eli Lilly here, it’s free. With a diverse portfolio of eight FDA-approved medications targeting neurological conditions, Supernus Pharmaceuticals (NASDAQ:SUPN) develops and markets treatments for central nervous system disorders including epilepsy, ADHD, Parkinson's disease, and migraine. Supernus Pharmaceuticals reported revenues of $211.3 million, up 27.7% year on year. This print beat analysts’ expectations by 2.8%. Overall, it was a very strong quarter as it also produced full-year operating income guidance exceeding analysts’ expectations and full-year revenue guidance slightly topping analysts’ expectations. The stock is up 9.3% since reporting and currently trades at $48.80. Read our full, actionable report on Supernus Pharmaceuticals here, it’s free. Over the past year, investors have been forced to repeatedly answer the same question: what is the market’s biggest risk? The answer has changed several times, and each shift has reshaped market leadership. Late in 2025 and early 2026, artificial intelligence became the market’s primary uncertainty. Investors questioned whether AI would erode software pricing power and weaken competitive moats as AI made it easier to replicate once-differentiated products. By the spring, technology took a back seat to geopolitics. The U.S. conflict with Iran briefly became the market’s dominant narrative, raising concerns about oil prices, inflation, and global growth. But as energy markets remained orderly and fears of a prolonged supply disruption faded, investors quickly turned their focus back to fundamentals. Want to invest in winners with rock-solid fundamentals? Check out our Top 5 Growth Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.

This article first appeared on GuruFocus. Revenue: $256.1 million in Q2 2026, a 32% increase year-over-year. Korlym and Authorized Generic Revenue: $208.6 million. Lifyorli Revenue: $47.6 million in its first quarter of availability. Net Income: $43 million in Q2 2026, compared to $35 million in the prior-year period. Cash and Investments: $545 million as of June 30, 2026. 2026 Revenue Guidance: Increased to a range of $1.1 billion to $1.2 billion. Warning! GuruFocus has detected 8 Warning Signs with CORT. Is CORT fairly valued? Test your thesis with our free DCF calculator. Release Date: July 29, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Record new prescriptions and first-time prescribers in Cushing's syndrome business, driving strong demand. Lifyorli launch in platinum-resistant ovarian cancer generated $47.6 million in first-quarter revenue with over 1,300 patients started. Positive CATALYST and MOMENTUM trial results are increasing physician awareness and screening for hypercortisolism. Relacorilant NDA resubmission accepted with PDUFA date of December 17, 2026, offering potential for accelerated growth. Promising Phase II DAZALS trial results for dazucorilant in ALS showed 84% reduction in risk of death at one year. Relacorilant's approval delayed due to a complete response letter from FDA, with resubmission only accepted in June 2026. Dazucorilant's gastrointestinal tolerability issues caused most discontinuations in the DAZALS trial. Lifyorli's duration of therapy is still early to assess, with limited long-term patient follow-up data. Potential competition from other therapies in Cushing's syndrome and oncology markets could impact growth. Dependence on successful Phase IIb MONARCH trial results for miricorilant in MASH, with data expected later this year. Q: Can you talk to the patient-level metrics on Lifyorli, including the number of patients on treatment currently, and whether the pace of patient adds is accelerating? Also, is the upward revision to guidance mostly related to the Lifyorli launch, and what are the dynamics surrounding Korlym?A: (Roberto Vieira, President - Oncology Division) We have initiated 1,300 patients on therapy since launch, with 1,000 unique prescribers. We are seeing a very broad range of patients, from early to late lines of therapy, and have maintained a strong pace of adding patients every week. We are on track to become market leaders and realize the $1 billion potential for platinum-resistant ovarian cancer. (Atabak Mokari, CFO) The new guidance range reflects strength across both our Endocrinology and Oncology businesses. Q: On Lifyorli, how much of the $48 million in revenue reflects dispensed demand versus initial channel build? Also, how many unique prescribers do you have beyond the 200 cited in April, and what is the duration of therapy? On Korlym, how much of the 27% sequential growth is from clearing the pharmacy transition backlog versus new capacity?A: (Atabak Mokari, CFO) There is very little inventory contribution in the quarter results. On the Cushing's syndrome side, almost 100% of business goes through specialty pharmacy, which is direct to patient. On the oncology side, about 30% goes through specialty pharmacy, and the rest through specialty distributors who hold minimal inventory (about one week of demand). (Sean Maduck, President - Corcept Endocrinology) The $44 million growth from Q2 over Q1 was not driven by a catch-up from the pharmacy transition, which is behind us. It was driven by continued servicing of our existing patient base and a record number of new enrollments. Q: What is the status of the relacorilant NDA resubmission for Cushing's syndrome, and what is the expected timeline for approval?A: (Joseph Belanoff, CEO) We resubmitted our NDA on June 17 after completing additional analyses requested by the FDA. The FDA accepted the resubmission and assigned a PDUFA date of December 17, 2026. Relacorilant's availability will accelerate growth in our Cushing's syndrome business. Q: What are the key results from the CATALYST and MOMENTUM trials, and how are they driving physician awareness and business growth?A: (Sean Maduck, President - Corcept Endocrinology) CATALYST showed 24% of patients with difficult-to-treat diabetes had hypercortisolism, and treatment with Korlym led to substantial reductions in HbA1c, weight, and waist circumference. MOMENTUM found 27% of patients with resistant hypertension had hypercortisolism. These paradigm-shifting findings are driving increased screening and treatment, leading to record new prescriptions and first-time prescribers. We expect this to propel our Cushing's syndrome business to at least $2 billion in annual revenue by the end of this decade. Q: What is the potential for GR antagonism in oncology beyond platinum-resistant ovarian cancer, and what are the upcoming data readouts?A: (Joseph Belanoff, CEO) GR antagonism has the potential to treat any solid tumor expressing the GR. Our BELLA trial (platinum-resistant and sensitive ovarian cancer, endometrial cancer), STELLA trial (cervical cancer), and TRIDENT trial (pancreatic cancer) will all produce results by the end of next year. Successful results could increase the number of patients relacorilant may help by fivefold. We also initiated the SYNERGY Phase Ib study of nenocorilant with nivolumab across solid tumors, with results expected by the end of next year. Q: What are the latest developments in the ALS program with dazucorilant, and what are the next steps?A: (Joseph Belanoff, CEO) In the DAZALS Phase II trial, patients receiving 300 mg of dazucorilant showed an 84% reduction in risk of death at one year (p=0.0009) and an 87% reduction at two years (p<0.0001). We are conducting a dose titration study to improve gastrointestinal tolerability, which caused most discontinuations. Findings will inform the design of a pivotal trial we plan to start early next year. Q: What is the status of the MASH program with miricorilant, and when can we expect data?A: (Joseph Belanoff, CEO) Our 175-patient Phase IIb MONARCH study has completed enrollment and will produce data later this year. In our Phase Ib study, miricorilant rapidly reduced liver fat and improved markers of liver health, including fibrosis, and was well tolerated. Positive results would support advancement to Phase III. Q: What are the key financial results for the second quarter of 2026?A: (Atabak Mokari, CFO) Revenue was $256.1 million, a 32% increase year-over-year. Korlym and authorized generic revenue was $208.6 million. Lifyorli product revenue was $47.6 million in its first quarter of availability. Net income was $43 million. We increased our 2026 revenue guidance to a range of $1.1 billion to $1.2 billion. Cash and investments at June 30 were $545 million. For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Corcept Therapeutics CORT reported second-quarter 2026 earnings of 36 cents per share, beating the Zacks Consensus Estimate of a loss of 4 cents. In the year-ago quarter, the company had reported earnings of 29 cents. Second-quarter revenues rose nearly 32% year over year to $256.1 million and surpassed the Zacks Consensus Estimate of $216 million. Growth was driven by higher Korlym sales and the first-quarter contribution from newly launched ovarian cancer drug Lifyorli (relacorilant). Year to date, shares of Corcept have surged 167.1% against the industry’s 2.4% decline. Image Source: Zacks Investment Research Corcept’s top line consisted of product sales from Cushing’s syndrome drug Korlym and newly launched ovarian cancer drug Lifyorli. In the second quarter of 2026, product revenues from Korlym were $208.6 million, up 7.3% year over year. However, the metric missed our model estimate of $212.2 million. In March 2026, the FDA approved Lifyorli, Corcept’s selective glucocorticoid receptor antagonist, in combination with nab-paclitaxel for the treatment of adult patients with platinum-resistant ovarian cancer. Lifyorli generated $47.6 million in its first quarter of commercial availability. The reported figure surpassed our model estimate of $2 million. More than 1,300 patients started treatment by the earnings update, while more than 1,000 physicians prescribed the drug. Management attributed uptake to Lifyorli’s efficacy and safety profile, oral administration and lack of a biomarker requirement. The regimen was listed as a preferred option in the NCCN Guidelines shortly after approval. Second-quarter operating expenses increased 28.1% year over year to $214.8 million. The rise reflected spending related to the Lifyorli launch and continued investment in the company’s Cushing’s syndrome business. Selling, general and administrative expenses surged 51.1% to $156.9 million. Research and development expenses declined 10.9% to $53.9 million. Corcept ended the quarter with cash and investments of $544.6 million, up from $515.4 million as of March 31, 2026. Corcept raised its 2026 revenue guidance to $1.1-$1.2 billion from the previous $950 million to $1.05 billion. Management said that the revised outlook reflects strength across the endocrinology and oncology businesses. The Zacks Consensus Estimate for revenues is pegged at $986.45 million. Corcept continued to make meaningful progress across its late-stage pipeline. The company resubmitted the new drug application (NDA) for relacorilant for the treatment of patients with hypercortisolism (Cushing's syndrome) to the FDA in June 2026. The FDA accepted the application and assigned a target action date of Dec. 17, 2026. The NDA filing is supported by positive data from the GRACE study, confirmatory evidence from the phase III GRADIENT study, long-term extension studies and a phase II study in hypercortisolism. Corcept is evaluating relacorilant plus nab-paclitaxel and bevacizumab in the phase II BELLA study in patients with platinum-resistant ovarian cancer to understand whether combining relacorilant with two medicines offers patients an additional treatment option or not. Top-line data are expected by the end of 2026. Additional studies investigating relacorilant across platinum-sensitive ovarian, endometrial, cervical and pancreatic cancers remain on track to report results by the end of 2027. Patient enrollment is ongoing in the mid-stage prostate cancer study. Corcept has submitted a marketing authorization application to the European Medicines Agency, seeking approval for relacorilant plus nab-paclitaxel for the treatment of patients with platinum-resistant ovarian cancer. A final decision in Europe is expected by the end of 2026. Beyond relacorilant, Corcept continues to advance its broader pipeline. Corcept is developing its other pipeline candidates, dazucorilant and miricorilant, in separate studies for treating amyotrophic lateral sclerosis (ALS) and biopsy-confirmed or presumed metabolic dysfunction-associated steatohepatitis, respectively. The phase IIb MONARCH study of miricorilant in patients with metabolic dysfunction-associated steatohepatitis has completed enrollment. Results are expected by the end of this year. Corcept is also conducting a dose-titration study of dazucorilant in ALS to improve gastrointestinal tolerability. The findings are expected to guide a planned phase III study after phase II DAZALS analyses showed substantial reductions in mortality risk at the 300-milligram dose. Corcept Therapeutics Incorporated price-consensus-eps-surprise-chart | Corcept Therapeutics Incorporated Quote Corcept currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the biotech sector are Harmony Biosciences HRMY and Liquidia Corporation LQDA, each currently sporting a Zacks Rank #1 (Strong Buy), and Neurocrine Biosciences NBIX, which carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. Over the past 90 days, earnings per share estimates for Harmony Biosciences have decreased from $3.34 to $3.30 for 2026. Over the same period, estimates for earnings per share increased from $3.79 to $3.87 for 2027. HRMY shares have lost 4.2% year to date. Harmony Biosciences missed on earnings in each of the trailing four quarters, delivering an average negative surprise of 25.16%. Over the past 90 days, estimates for Liquidia’s 2026 earnings per share have increased to $3.02 from $1.50. Over the same period, EPS estimates for 2027 have risen to $5.31 from $2.91. LQDA shares have gained 151.7% year to date. Liquidia’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 54.40%. Over the past 90 days, estimates for Neurocrine Biosciences’ 2026 earnings per share have risen from $8 to $9.09. Over the same period, EPS estimates for 2027 have increased from $9.48 to $10.81. NBIX shares have gained 27.5% year to date. Neurocrine Biosciences’ earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 9.08%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Corcept Therapeutics Incorporated (CORT) : Free Stock Analysis Report Neurocrine Biosciences, Inc. (NBIX) : Free Stock Analysis Report Liquidia Corporation (LQDA) : Free Stock Analysis Report Harmony Biosciences Holdings, Inc. (HRMY) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Revenue of $256.1 million, a 32 percent increase over the same period in 2025 Increase in 2026 revenue guidance to $1.1 – $1.2 billion Net income of $43.0 million, compared to $35.1 million in second quarter 2025 Cash and investments of $544.6 million at June 30, 2026 REDWOOD CITY, Calif., July 29, 2026--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended June 30, 2026. Financial Results "Our oncology and Cushing’s syndrome businesses delivered strong results in the second quarter. In our oncology business, over 1,300 patients have now started treatment with Lifyorli following FDA approval in March 2026. Demand for Lifyorli has accelerated each month with physicians responding favorably to Lifyorli’s efficacy and safety profile, oral administration and lack of biomarker requirement. Our Cushing’s syndrome business, once again, had a record number of new prescriptions written for our medications as physicians increasingly recognize hypercortisolism’s true prevalence and the necessity of appropriate treatment. We expect this trend to continue as the findings from our CATALYST and MOMENTUM studies are fully incorporated into clinical practice. We anticipate continued strength across our businesses and have increased our 2026 revenue guidance to $1.1 – $1.2 billion," said Joseph K. Belanoff, M.D., Corcept’s Chief Executive Officer. Corcept’s second quarter 2026 revenue was $256.1 million, compared to $194.4 million in the second quarter of 2025. Korlym and authorized generic product revenue was $208.6 million, compared to $194.4 million in the prior year period. Lifyorli product revenue was $47.6 million in its first quarter of availability. Second quarter 2026 operating expenses were $214.8 million, compared to $167.8 million in the same period in 2025, due to increased spending to launch Lifyorli and investments in our Cushing’s syndrome business. Net income per common share (diluted) was $0.36 in the second quarter of 2026, compared to $0.29 in the prior year period. Cash and investments were $544.6 million at June 30, 2026, compared to $515.4 million at March 31, 2026. Clinical Development "The FDA’s approval of Lifyorli (relacorilant) in platinum-resistant ovarian cancer is the first step in advancing glucocorticoid receptor antagonism as a treatment for many types of cancer. Our oncology development program aims to establish the broad utility of our medicines to help many more patients. We anticipate that the European Medicines Agency will approve our Marketing Authorization Application of relacorilant in platinum-resistant ovarian cancer later this year. We expect results from our trial of relacorilant with nab-paclitaxel and bevacizumab in patients with platinum-resistant ovarian cancer by the end of this year. Our studies of relacorilant to treat platinum-sensitive ovarian, endometrial, cervical and pancreatic cancers are expected to produce results by the end of next year. Our study of nenocorilant with the PD-1 checkpoint inhibitor nivolumab to treat a variety of solid tumors will also produce results by the end of next year," said Dr. Belanoff. "We resubmitted our New Drug Application (NDA) for relacorilant in Cushing’s syndrome in June. Relacorilant has the potential to help many patients and it’s important it is available as quickly as possible. We expect a decision on our NDA by December 17, 2026. In addition, results from MONARCH, our Phase 2b trial in patients with metabolic dysfunction-associated steatohepatitis (MASH), are expected by the end of this year. We also plan to start a Phase 3 trial of dazucorilant in patients with ALS, with the goal of replicating the significant survival benefit observed in our Phase 2 DAZALS study," added Dr. Belanoff. Hypercortisolism (Cushing’s Syndrome) Relacorilant for patients with Cushing’s syndrome – New Drug Application for relacorilant resubmitted with a Prescription Drug User Fee Act (PDUFA) date of December 17, 2026 GRACE – Pivotal Phase 3 trial of relacorilant in 152 patients with Cushing’s syndrome – Results published in The Lancet Diabetes & Endocrinology (Pivonello et al, February 2026) CATALYST and MOMENTUM – New data presented at American Diabetes Association’s (ADA) 86th Scientific Sessions in June "Our studies have shown that patients with hypercortisolism who receive relacorilant experience clinically and statistically significant improvements in the multiple signs and symptoms of the disease. Importantly, relacorilant delivers these improvements without the off-target effects and serious adverse events associated with currently available treatments," said Bill Guyer, PharmD, Corcept’s Chief Development Officer. "Relacorilant has the potential to become the new standard of care." "The need for better treatment for patients with hypercortisolism is urgent. Our CATALYST and MOMENTUM studies demonstrate that hypercortisolism is an underlying driver of disease for many patients with diabetes and hypertension whose health is at risk because their disease isn’t adequately managed with standard-of-care treatments. These findings will lead to increased screening and improved treatment for patients with hypercortisolism," added Dr. Guyer. Oncology Relacorilant in Combination with Chemotherapy FDA approved Lifyorli (relacorilant) plus nab-paclitaxel for the treatment of patients with platinum-resistant ovarian cancer in March 2026 Lifyorli plus nab-paclitaxel added to the National Comprehensive Cancer Network® Clinical Practice Guidelines in Oncology (NCCN Guidelines®) as a preferred regimen in April 2026 Marketing Authorization Application (MAA) – European Medicines Agency reviewing MAA for relacorilant plus nab-paclitaxel to treat patients with platinum-resistant ovarian cancer – Approval expected by the end of this year ROSELLA – Pivotal Phase 3 trial of relacorilant plus nab-paclitaxel in 381 patients with platinum-resistant ovarian cancer – Both dual primary endpoints (progression-free and overall survival) met – Results published in The Lancet (Lorusso et al, April 2026) BELLA Part A – Enrollment completed in Phase 2 trial of relacorilant plus nab-paclitaxel and bevacizumab in 95 patients with platinum-resistant ovarian cancer – Results expected by the end of this year BELLA Part B – Enrollment continues in Phase 2 trial of relacorilant plus nab-paclitaxel and bevacizumab in 90 patients with platinum-sensitive ovarian cancer whose disease progressed while on a PARP inhibitor – Results expected by the end of next year BELLA Part C – Enrollment continues in Phase 2 trial of relacorilant plus nab-paclitaxel in 90 patients with endometrial cancer (who have received one or two prior lines of therapy) – Results expected by the end of next year STELLA – Initiated Phase 2 trial of relacorilant plus nab-paclitaxel in 50 patients with cervical cancer (received one or two prior lines of therapy), conducted in collaboration with ARCAGY-GINECO – Results expected by the end of next year TRIDENT – Enrollment continues in Phase 2 trial of relacorilant plus nab-paclitaxel and gemcitabine as first-line therapy in 60 patients with pancreatic cancer – Results expected by the end of next year Relacorilant in Combination with Androgen Deprivation Therapy Prostate cancer – Enrollment continues in randomized, placebo-controlled Phase 2 trial of relacorilant plus enzalutamide in 90 patients with early-stage prostate cancer, conducted in collaboration with the University of Chicago Nenocorilant in Combination with Immunotherapy SYNERGY – Enrollment continues in Phase 1b dose-finding trial of nenocorilant plus nivolumab in 30 patients with a variety of solid tumors – Results expected by the end of next year "There is tremendous potential for glucocorticoid receptor antagonism to help treat many types of solid tumors. Our Phase 3 ROSELLA trial demonstrated that adding Lifyorli to nab-paclitaxel chemotherapy reduced the risk of death in patients with platinum-resistant ovarian cancer by 35 percent, without the need for biomarker selection. Our ongoing oncology studies, many of which will produce results by the end of next year, build on these findings by evaluating the role of our medications across a broad range of tumor types and treatment combinations. We will continue to advance and expand our research to realize the substantial opportunity before us," added Dr. Guyer. Metabolic Dysfunction-Associated Steatohepatitis (MASH) MONARCH – Enrollment completed in randomized, double-blind, placebo-controlled, Phase 2b trial of miricorilant in 175 patients with biopsy-confirmed or presumed MASH – Results expected by the end of this year "Data from our Phase 1b study demonstrated that miricorilant rapidly reduced liver fat while improving fibrosis, liver enzymes and other markers of liver health, including key metabolic and lipid measures. We look forward to building on these promising findings in our Phase 2b MONARCH study, with results expected by the end of this year," said Dr. Guyer. Amyotrophic Lateral Sclerosis (ALS) DAZALS – Exploratory analyses showed that patients who received dazucorilant 300 mg exhibited an 84 percent reduction in risk of death during the study’s first year compared to patients who received placebo (hazard ratio: 0.16, p-value: 0.0009) – This benefit persisted into the study’s second year with an 87 percent reduction in risk of death (hazard ratio: 0.13, p-value: Phase 3 trial – Planned to begin early next year "Patients with ALS often have elevated cortisol levels. Data from our Phase 2 DAZALS study showed that patients treated with dazucorilant exhibited a profound reduction in early mortality, during a period when many patients with ALS still retain significant function and maintain good quality of life," said Dr. Guyer. "Our ongoing dose-titration study’s goal is to improve gastrointestinal tolerability and inform next steps for this program." Conference Call We will hold a conference call on July 29, 2026, at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number and a unique access PIN. Each access PIN will accommodate one caller. A listen-only webcast will be available by clicking here. A replay of the call will be available on the Investors / Events tab of Corcept.com. About Corcept Therapeutics For over 25 years, Corcept has focused on cortisol modulation and its potential to treat patients with a wide variety of serious disorders, leading to the discovery of more than 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists. Corcept is conducting advanced clinical trials in patients with Cushing’s syndrome, solid tumors, ALS and liver disease. In 2012, the company introduced Korlym®, the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with endogenous Cushing’s syndrome, and in 2026, the company introduced Lifyorli, approved in combination with nab-paclitaxel, the first FDA-approved selective glucocorticoid receptor antagonist for adults with platinum-resistant ovarian cancer. Corcept is headquartered in Redwood City, California. For more information, visit Corcept.com. Forward-Looking Statements Statements in this press release, other than statements of historical fact, are forward-looking statements based on our current plans and expectations and are subject to risks and uncertainties that might cause our actual results to differ materially from any future results expressed or implied by such forward-looking statements. In this press release, forward-looking statements include those concerning: the anticipated continued strength across our businesses; our 2026 revenue guidance; our expectation that the trend related to the number of new prescriptions written for our medications will continue as physicians increasingly recognize the prevalence of hypercortisolism and the necessity of treatment; the potential for glucocorticoid receptor antagonism to be a treatment for many types of cancer and solid tumors; our anticipation that the European Medicines Agency will approve our MAA for relacorilant plus nab-paclitaxel to treat patients with platinum-resistant ovarian cancer this year; resubmission of our NDA for relacorilant for the treatment of patients with Cushing’s syndrome and our expectation that the FDA will issue a decision on this NDA by December 17, 2026; the potential for relacorilant to help many patients and the importance of relacorilant becoming available as quickly as possible; statements related to ongoing oncology clinical trials of relacorilant or nenocorilant in combination with nab-paclitaxel, other chemotherapy, androgen deprivation therapy or immunotherapy, including statements regarding the potential to produce important data, expected patient enrollment, and the expected timing of results from these trials; our plan to begin a Phase 3 trial in the treatment of patients with ALS early next year with the goal of replicating the significant survival benefit observed in our Phase 2 DAZALS study; relacorilant’s potential to become the new standard of care for treatment of patients with hypercortisolism; the findings of our CATALYST and MOMENTUM studies and the possibility that these findings will lead to increased screening and improved treatment for patients with hypercortisolism; the expectation that we will have results from our Phase 2b MONARCH study of miricorilant in patients with MASH by the end of 2026 and our ability to build on the findings from this study; and our intent to use our ongoing dose-titration study of dazucorilant to improve gastrointestinal tolerability of treatment and inform next steps for our ALS program. A further description of risks and uncertainties can be found in our SEC filings, which are available at our website and the SEC’s website. These risks and uncertainties include, but are not limited to, those related to our ability to: operate our business; study and develop Korlym, relacorilant, miricorilant, dazucorilant, nenocorilant and our other product candidates; those molecules’ clinical attributes, regulatory approvals, mandates, oversight and other requirements; and the scope and protective power of our intellectual property. We disclaim any intention or duty to update forward-looking statements made in this press release. View source version on businesswire.com: https://www.businesswire.com/news/home/20260729465503/en/ Contacts Investor inquiries:[email protected] Media inquiries:[email protected] www.corcept.com